CDER’s Outlook problems
Executive Summary
Some senior FDA officials failed to publicize meetings, as required, from January 1999 through December of 2006, according to reports compiled by House Energy and Commerce Republican staffers. The calendar listings, reviewed in preparation for hearings on drug safety legislation, contained three entries for former CDER Director Janet Woodcock and none for her successor, Steven Galson, as well as missing data for former Deputy Commissioner Scott Gottlieb and other center directors, the report shows. FDA admitted that public calendar listings "were not as inclusive as they should have been because of administrative oversight." Unreported meetings are now being added, according to a written response from the agency to the House committee. As opposed to the drug officials, listings for the Director for Veterinary Medicine Stephen Sundlof contain 263 publicized meetings during the studied time frame...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.